Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.


Journal

Current protocols in microbiology
ISSN: 1934-8533
Titre abrégé: Curr Protoc Microbiol
Pays: United States
ID NLM: 101257113

Informations de publication

Date de publication:
12 2020
Historique:
entrez: 28 9 2020
pubmed: 29 9 2020
medline: 13 7 2021
Statut: ppublish

Résumé

Cryptococcus neoformans, an opportunistic yeast-like fungal pathogen, has demonstrated resistance to all major classes of antifungals used to treat cryptococcal meningitis. However, combatting this fungal disease is an ongoing challenge among clinicians due to the evolution of antifungal-resistant strains. The limited availability of clinically approved antifungals has heightened the urgency to investigate the molecular mechanisms underscoring resistance. Studying how a fungal pathogen evolves to an antifungal drug in vitro using experimental evolution provides a simple, yet powerful approach to study the mechanisms of antifungal resistance. Experimental evolution involves the serial passaging of microbial populations under laboratory conditions, such that adaptive mutations can occur and be monitored in real time. This technique plays a key role in investigating the mechanisms of antifungal resistance in C. neoformans, and this can help in developing novel strategies to combat the emergence of resistance. Here, we outline how to make overnight cultures of C. neoformans and how to perform experimental evolution, and we present a spectrophotometric analysis to evaluate the evolution of antifungal resistance. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Growth and sample preparation of Cryptococcus neoformans Basic Protocol 2: Experimental evolution of antifungal resistance Basic Protocol 3: Analyzing the evolution of antifungal resistance Basic Protocol 4: Glycerol stock preparation.

Identifiants

pubmed: 32986290
doi: 10.1002/cpmc.116
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e116

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Ball, B., Bermas, A., Carruthers-Lay, D., & Geddes-McAlister, J. (2019). Mass spectrometry-based proteomics of fungal pathogenesis, host-fungal interactions, and antifungal development. Journal of Fungi, 5, 52. doi: 10.3390/jof5020052.
Ball, B., & Geddes-McAlister, J. (2019). Quantitative proteomic profiling of Cryptococcus neoformans. Current Protocols in Microbiology, 55, e94. doi: 10.1002/cpmc.94.
Barlow, M., & Hall, B. G. (2003). Experimental prediction of the natural evolution of antibiotic resistance. Genetics, 163, 1237-1241.
Bermas, A., & Geddes-McAlister, J. (2020). Combatting the evolution of anti-fungal resistance in Cryptococcus neoformans. Molecular Microbiology, Epub ahead of print. doi: 10.1111/mmi.14565.
Billmyre, R., Clancey, S., Li, L., Doering, T., & Heitman, J. (2020). 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nature Communications, 11, 127. doi: 10.1038/s41467-019-13890-z.
Bongomin, F., Oladele, R. O., Gago, S., Moore, C. B., & Richardson, M. D. (2018). A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses, 61, 290-297. doi: 10.1111/myc.12747.
Chang, Y. C., Stins, M. F., McCaffery, M. J., Miller, G. F., Pare, D. R., Dam, T., … Kwon-Chung, K. J. (2004). Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infection and Immunity, 72, 4985-4995. doi: 10.1128/IAI.72.9.4985-4995.2004.
Cowen, L. E., Sanglard, D., Calabrese, D., Sirjusingh, C., Anderson, J. B., & Kohn, L. M. (2000). Evolution of drug resistance in experimental populations of Candida albicans. Journal of Bacteriology, 182, 1515-1522. doi: 10.1128/jb.182.6.1515-1522.2000.
Dromer, F., & Levitz, S. M. (2014). Invasion of Cryptococcus into the central nervous system. In J. Heitman, T. R. Kozel, K. J. Kwon-Chung, J. R. Perfect & A. Casadevall (Eds.), Cryptococcus. Washington, D.C.: ASM Press. doi: 10.1128/9781555816858.ch34.
Dunham, M. J., Badrane, H., Ferea, T., Adams, J., Brown, P. O., Rosenzweig, F., & Botstein, D. (2002). Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America, 99, 16144-16149. doi: 10.1073/pnas.242624799.
Geddes-McAlister, J., & Shapiro, R. S. (2018). New pathogens, new tricks: Emerging, drug-resistant fungal pathogens and future prospects for antifungal therapeutics. Annals of the New York Academy of Sciences, 1435, 57-78. doi: 10.1111/nyas.13739.
Gresham, D., Usaite, R., Germann, S. M., Lisby, M., Botstein, D., & Regenberg, B. (2010). Adaptation to diverse nitrogen-limited environments by deletion or extrachromosomal element formation of the GAP1 locus. Proceedings of the National Academy of Sciences of the United States of America, 107, 18551-18556. doi: 10.1073/pnas.1014023107.
Kneale, M., Bartholomew, J. S., Davies, E., & Denning, D. W. (2016). Global access to antifungal therapy and its variable cost. Journal of Antimicrobial Chemotherapy, 71, 3599-3606. doi: 10.1093/jac/dkw325.
Norrby, S. R., Nord, C. E., & Finch, R. (2005). Lack of development of new antimicrobial drugs: A potential serious threat to public health. The Lancet Infectious Diseases, 5, 115-119. doi: 10.1016/s1473-3099(05)01283-1.
Perfect, J. R. (2017). The antifungal pipeline: A reality check. Nature Reviews Drug Discovery, 16, 603-616. doi: 10.1038/nrd.2017.46.
Perfect, J. R., & Cox, G. M. (1999). Drug resistance in Cryptococcus neoformans. Drug Resistance Updates, 2, 259-269. doi: 10.1054/drup.1999.0090.
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., … Boulware, D. R. (2017). Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. The Lancet Infectious Diseases, 17, 873-881. doi: 10.1016/S1473-3099(17)30243-8.
Sanglard, D. (2019). Finding the needle in a haystack: Mapping antifungal drug resistance in fungal pathogen by genomic approaches. PLoS Pathogens, 15, e1007478. doi: 10.1371/journal.ppat.1007478.
Santiago-Tirado, F. H., Onken, M. D., Cooper, J. A., Klein, R. S., & Doering, T. L. (2017). Trojan horse transit contributes to blood-brain barrier crossing of a eukaryotic pathogen. mBio, 8, e02183-16. doi: 10.1128/mBio.02183-16.
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013). Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biology, 11, e1001692. doi: 10.1371/journal.pbio.1001692.
Wiederhold, N. P. (2017). Antifungal resistance: Current trends and future strategies to combat. Infection and Drug Resistance, 10, 249-259. doi: 10.2147/IDR.S124918.
Xu, J. (2016). Fungal DNA barcoding. Genome, 59, 913-932. doi: 10.1139/gen-2016-0046.

Auteurs

Arianne Bermas (A)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Jennifer Geddes-McAlister (J)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH